Cancer Therapy AdvisorNCCN NSCLC Guidelines Update Staging, Emphasize Molecular Testing

The NCCN NSCLC guidelines (Version 3, 2026) add sevabertinib for HER2-mutated advanced disease, elevate datopotamab deruxtecan-dlink to preferred second-line status post-osimertinib, and realign staging with AJCC 9th edition, reshaping molecular testing and treatment sequencing across disease stages.

🔬 CLINICAL CONSIDERATIONS

• Sevabertinib is now preferred for previously treated advanced/metastatic NSCLC with ERBB2 (HER2) mutations. Patients with prior sevabertinib exposure are explicitly excluded.
• Datopotamab deruxtecan-dlink gains preferred status in multiple lines: post-osimertinib plus chemo progression, third-line relapsed/refractory disease, and select EGFR exon 19, 20, and rare mutation subtypes
• Osimertinib plus chemotherapy and amivantamab plus lazertinib are now co-preferred frontline options for treatment-naive EGFR-mutated disease, expanding frontline decision complexity
• Stage IB-IIIA/IIB patients now require biomarker evaluation — PD-L1, EGFR, ALK — before neoadjuvant/adjuvant systemic therapy decisions
• Subcutaneous pembrolizumab plus berahyaluronidase alfa is now interchangeable with IV pembrolizumab for advanced/metastatic disease, an operational efficiency for infusion centers

🎯 PRACTICE APPLICATIONS

• Update molecular testing protocols to capture HER2/ERBB2 mutations in all eligible advanced NSCLC patients prior to second-line selection
• Integrate AJCC 9th edition staging criteria into institutional tumor board and staging workflows immediately
• Reassess stage IB-IIIA/IIB patients lacking complete biomarker profiles before initiating perioperative systemic therapy
• Evaluate subcutaneous pembrolizumab conversion for appropriate patients to reduce chair time and infusion burden

More on Lung Cancer